Lupin Limited announced completion of its acquisition of European ophthalmology specialist VISUfarma B.V. from GHO Capital Partners.
The deal expands Lupin’s eye‑care portfolio to over 60 branded products and strengthens its presence in Italy, UK, Spain, Germany and France.
VISUfarma generated €53 million revenue in 2025 across its European markets, positioning Lupin to tap demand from ageing populations and diabetes‑related eye complications.
CEO Vinita Gupta said the acquisition is immediately accretive and will accelerate Lupin’s specialty franchise build‑out across Europe.